MedKoo product information:

Rostaporfin

The photosensitiser rostaporfin [Purlytin trade mark, SnET2, tin ethyl etiopurpurin, Sn(IV) etiopurpurin, PhotoPoint SnET2] was developed by Miravant Medical Technologies (USA) for use in the company's PhotoPoint trade mark photodynamic therapy. The therapy relies on low power, non-thermal light produced by a solid-state diode laser, sourced from the device co-developing partner, Iredex Corporation. Mirvant is currently undergoing discussions for potential licensing agreements with leading ophthalmology companies for rostaporfin. In June 2002, Miravant and Bausch & Lomb signed a non-binding letter on intent. The companies are expected to jointly review phase III clinical data concerning rostaporfin. Following the review Bausch & Lomb may negotiate an exclusive worldwide license to develop and commercialise the agent for ophthalmological indications. Previously, in June 1995, Miravant granted Pharmacia & Upjohn (now Pfizer) an exclusive worldwide license for development and marketing of rostaporfin. However, this agreement was terminated in March 2002, at which time Miravant regained the rights to all assets related to rostaporfin. In April 2000, Monsanto merged with Pharmacia & Upjohn to form Pharmacia Corporation. Subsequently, on 16 April 2003, Pharmacia Corporation was acquired by, and merged into, Pfizer. Preclinical studies had been underway for other vision-threatening eye diseases, as it also has potential in the treatment of diabetic retinopathy and glaucoma. The US FDA had granted fast-track status to rostaporfin for the treatment of age-related macular degeneration in 1998. [source: Drugs R D. 2004;5(1):58-61.]

Pharmacia Corp, under license from Miravant Medical Technologies (formerly PDT Inc), is developing rostaporfin (SnET2, Purlytin), a light-activated cytotoxic drug developed as part of Miravant's PhotoPoint photodynamic therapy (PDT) program, for the potential treatment of wet age-related macular degeneration (AMD) [180314]. In January 2002, results of phase III trials indicated that rostaporfin had not met the primary efficacy endpoint for the wet form of AMD. At this time, a full review of the data was to be undertaken, and decisions about future development of the drug were to be made after additional analyses had been completed [435577]. The original licensing agreements included the development of rostaporfin for several ophthalmology, oncology and urology indications [289078], and for dermatological applications including certain skin cancers [267521]. However, in August 1998, Miravant reported that it no longer intended to pursue cutaneous metastatic breast cancer (CMBC), in order to focus on AMD [439372], [439384]. Also in 1998, studies in basal cell carcinoma and AIDS-related Kaposi's sarcoma were discontinued because of business considerations [439372]. Rostaporfin is activated by red light with a wavelength of 664 nm. It is injected into the patient, where it distributes and selectively binds to plasma lipoproteins, which are produced in high concentrations by hyperproliferating cells such as cancer cells. After 24 h, the targeted cells are stimulated by red light to activate the compound. This triggers the formation of toxic free radical species that destroy the cells without affecting the surrounding normal tissue [85236]. In January 2002, Credit Suisse First Boston estimated sales for Pharmacia of 40 million US dollars in 2003 and 80 million US dollars in 2004 [436118], while in the same month, Argus Research predicted peak annual sales for Pharmacia of less than 250 million US dollars[436279]. [source: IDrugs. 2002 Feb;5(2):180-6.]

Current developer:    Miravant Medical Technologies; Pharmacia Corp.

1: Sivaprasad S, Hykin P. The role of photodynamic therapy in ophthalmology. Br J Hosp Med (Lond). 2006 Dec;67(12):647-50. Review. PubMed PMID: 17328448.

2: Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot-Garcher C, Dimitrakos SA 2nd, Korobelnik JF, Larsen M, Monés J, Pauleikhoff D, Pournaras CJ, Staurenghi G, Virgili G, Wolf S. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol. 2006 Sep;90(9):1188-96. PubMed PMID: 16929063; PubMed Central PMCID: PMC1857411.

3: Jankun J, Keck RW, Skrzypczak-Jankun E, Lilge L, Selman SH. Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy. BJU Int. 2005 Jun;95(9):1237-44. PubMed PMID: 15892808.

4: Skrzypczak-Jankun E, Borbulevych OY, Melillo A, Keck R, Soriano-Garcia M, Aniola J, Niedre M, Lilge L, Selman SH, Jankun J. Aspirin blocks binding of photosensitizer SnET2 into human serum albumin: implications for photodynamic therapy. Int J Mol Med. 2005 May;15(5):777-83. PubMed PMID: 15806298.

5: Zimcík P, Miletín M. [Photodynamic therapy as a new prospective method for cancer treatment--II. Overview of photosensitizers]. Ceska Slov Farm. 2004 Nov;53(6):271-9. Review. Czech. PubMed PMID: 15630992.

6: Poriel C, Kessel D, Vicente MG. Stability of tin etiopurpurin. Photochem Photobiol. 2005 Jan-Feb;81(1):149-53. PubMed PMID: 15560741.

7: Lilge L, Pomerleau-Dalcourt N, Douplik A, Selman SH, Keck RW, Szkudlarek M, Pestka M, Jankun J. Transperineal in vivo fluence-rate dosimetry in the canine prostate during SnET2-mediated PDT. Phys Med Biol. 2004 Jul 21;49(14):3209-25. PubMed PMID: 15357193.

8: Jankun J, Lilge L, Douplik A, Keck RW, Pestka M, Szkudlarek M, Stevens PJ, Lee RJ, Selman SH. Optical characteristics of the canine prostate at 665 nm sensitized with tin etiopurpurin dichloride: need for real-time monitoring of photodynamic therapy. J Urol. 2004 Aug;172(2):739-43. PubMed PMID: 15247773.

9: Gloi AM, Beck E. Threshold dose of three photosensitizers in dogs with spontaneous tumors. Vet Ther. 2003 Fall;4(3):269-78. PubMed PMID: 15136988.

10: Rostaporfin: PhotoPoint SnET2, Purlytin, Sn(IV) etiopurpurin, SnET2, tin ethyl etiopurpurin. Drugs R D. 2004;5(1):58-61. Review. PubMed PMID: 14725496.

11: Garbo GM, Vicente MG, Fingar V, Kessel D. Effects of ursodeoxycholic acid on photodynamic therapy in a murine tumor model. Photochem Photobiol. 2003 Oct;78(4):407-10. PubMed PMID: 14626670.

12: Gloi AM, Beck E. Biodistribution of three photosensitizers in dogs with spontaneous tumors. Vet Ther. 2003 Summer;4(2):155-65. PubMed PMID: 14506591.

13: Hunt DW. Rostaporfin (Miravant Medical Technologies). IDrugs. 2002 Feb;5(2):180-6. PubMed PMID: 12861479.

14: Zennaro D, Wellig P, Koch VM, Moschytz GS, Läubli T. A software package for the decomposition of long-term multichannel EMG signals using wavelet coefficients. IEEE Trans Biomed Eng. 2003 Jan;50(1):58-69. PubMed PMID: 12617525.

15: Ning MY, Li TF, Li QS. [Study of the interactions between diorganotin (IV) complexes of 1,3-dimethyl-4-acetyl-5-pyrazolone and mononucleotides and DNA]. Yao Xue Xue Bao. 2002 Jun;37(6):433-6. Chinese. PubMed PMID: 12579799.

16: Aniola J, Selman SH, Lilge L, Keck R, Jankun J. Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy. Int J Mol Med. 2003 Mar;11(3):287-91. PubMed PMID: 12579328.

17: Lim JI. Photodynamic therapy for choroidal neovascular disease: photosensitizers and clinical trials. Ophthalmol Clin North Am. 2002 Dec;15(4):473-8, vii. Review. PubMed PMID: 12515080.

18: Woodburn KW, Engelman CJ, Blumenkranz MS. Photodynamic therapy for choroidal neovascularization: a review. Retina. 2002 Aug;22(4):391-405; quiz 527-8. Review. PubMed PMID: 12172104.

19: Renno RZ, Miller JW. Photosensitizer delivery for photodynamic therapy of choroidal neovascularization. Adv Drug Deliv Rev. 2001 Oct 31;52(1):63-78. Review. PubMed PMID: 11672876.

20: Shuler MF, Borrillo JL, Ho AC. Photodynamic therapy update. Curr Opin Ophthalmol. 2001 Jun;12(3):202-6. Review. PubMed PMID: 11389347.

21: Selman SH, Albrecht D, Keck RW, Brennan P, Kondo S. Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate. J Urol. 2001 May;165(5):1795-801. PubMed PMID: 11342978.

22: Pogue BW, Ortel B, Chen N, Redmond RW, Hasan T. A photobiological and photophysical-based study of phototoxicity of two chlorins. Cancer Res. 2001 Jan 15;61(2):717-24. PubMed PMID: 11212274.

23: Kessel D, Caruso JA, Reiners JJ Jr. Potentiation of photodynamic therapy by ursodeoxycholic acid. Cancer Res. 2000 Dec 15;60(24):6985-8. PubMed PMID: 11156400.

24: DuBosar R. Age-related macular degeneration: new treatments show promise. J Ophthalmic Nurs Technol. 1999 Mar-Apr;18(2):60-4. PubMed PMID: 10409997.

25: Pogue BW, Redmond RW, Trivedi N, Hasan T. Photophysical properties of tin ethyl etiopurpurin I (SnET2) and tin octaethylbenzochlorin (SnOEBC) in solution and bound to albumin. Photochem Photobiol. 1998 Dec;68(6):809-15. PubMed PMID: 9867030.

26: Mang TS, Allison R, Hewson G, Snider W, Moskowitz R. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J Sci Am. 1998 Nov-Dec;4(6):378-84. PubMed PMID: 9853137.

27: Primbs GB, Casey R, Wamser K, Snyder WJ, Crean DH. Photodynamic therapy for corneal neovascularization. Ophthalmic Surg Lasers. 1998 Oct;29(10):832-8. PubMed PMID: 9793949.

28: Moshfeghi DM, Peyman GA, Moshfeghi AA, Khoobehi B, Primbs GB, Crean DH. Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies. Ophthalmic Surg Lasers. 1998 Aug;29(8):663-8. PubMed PMID: 9715492.

29: Lilge L, Wilson BC. Photodynamic therapy of intracranial tissues: a preclinical comparative study of four different photosensitizers. J Clin Laser Med Surg. 1998 Apr;16(2):81-91. PubMed PMID: 9663099.

30: Kaplan MJ, Somers RG, Greenberg RH, Ackler J. Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2). J Surg Oncol. 1998 Feb;67(2):121-5. PubMed PMID: 9486784.

31: Simkin GO, King DE, Levy JG, Chan AH, Hunt DW. Inhibition of contact hypersensitivity with different analogs of benzoporphyrin derivative. Immunopharmacology. 1997 Oct;37(2-3):221-30. PubMed PMID: 9403341.

32: Hill RA, Crean DH, Doiron DR, Ghosheh F, Ryan JA, Kelly H, Booth M, Liaw LH, Newman L, Berns MW. Photodynamic therapy of the ciliary body with tin ethyl etiopurpurin and tin octaethyl benzochlorin in pigmented rabbits. Ophthalmic Surg Lasers. 1997 Nov;28(11):948-53. PubMed PMID: 9387183.

33: Fisher AM, Danenberg K, Banerjee D, Bertino JR, Danenberg P, Gomer CJ. Increased photosensitivity in HL60 cells expressing wild-type p53. Photochem Photobiol. 1997 Aug;66(2):265-70. PubMed PMID: 9277147.

34: Rifkin R, Reed B, Hetzel F, Chen K. Photodynamic therapy using SnET2 for basal cell nevus syndrome: a case report. Clin Ther. 1997 Jul-Aug;19(4):639-41. PubMed PMID: 9377609.

35: Lilge L, O'Carroll C, Wilson BC. A solubilization technique for photosensitizer quantification in ex vivo tissue samples. J Photochem Photobiol B. 1997 Jul;39(3):229-35. PubMed PMID: 9253199.

36: Hill RA, Crean DH, Doiron DR, McDonald TJ, Liaw LH, Ghosheh F, Hamilton A, Berns MW. Photodynamic therapy for antifibrosis in a rabbit model of filtration surgery. Ophthalmic Surg Lasers. 1997 Jul;28(7):574-81. PubMed PMID: 9243661.

37: Peyman GA, Moshfeghi DM, Moshfeghi A, Khoobehi B, Doiron DR, Primbs GB, Crean DH. Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2). Ophthalmic Surg Lasers. 1997 May;28(5):409-17. PubMed PMID: 9150524.

38: Kessel D, Luo Y, Deng Y, Chang CK. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol. 1997 Mar;65(3):422-6. PubMed PMID: 9077123.

39: Gomer CJ, Luna M, Ferrario A, Wong S, Fisher AM, Rucker N. Cellular targets and molecular responses associated with photodynamic therapy. J Clin Laser Med Surg. 1996 Oct;14(5):315-21. Review. PubMed PMID: 9612198.

40: Rocklin GB, Kelly HG, Anderson SC, Edwards LE, Gimpelson RJ, Perez RE. Photodynamic therapy of rat endometrium sensitized with tin ethyl etiopurpurin. J Am Assoc Gynecol Laparosc. 1996 Aug;3(4):561-70. PubMed PMID: 9050689.

41: Selman SH, Keck RW, Hampton JA. Transperineal photodynamic ablation of the canine prostate. J Urol. 1996 Jul;156(1):258-60. PubMed PMID: 8648818.

42: PDT therapy for KS shows promising results. AIDS Patient Care STDS. 1996 Apr;10(2):135. PubMed PMID: 11361703.

43: Luo Y, Chang CK, Kessel D. Rapid initiation of apoptosis by photodynamic therapy. Photochem Photobiol. 1996 Apr;63(4):528-34. PubMed PMID: 8934765.

44: Coats WD Jr, Currier JW, Mejias Y, Narciso HL, Faxon DP. Tin ethyl etiopurpurin significantly inhibits vascular smooth muscle cell proliferation in vivo. Biochem Cell Biol. 1996;74(3):325-31. PubMed PMID: 8883838.

45: Lee LK, Whitehurst C, Pantelides ML, Moore JV. In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland. Photochem Photobiol. 1995 Nov;62(5):882-6. PubMed PMID: 8570727.

46: Kongshaug M, Moan J, Cheng LS, Morgan AR. Binding of etiopurpurin to human plasma proteins. Delivery in cremophor EL and dimethyl sulphoxide. III. Int J Biochem Cell Biol. 1995 May;27(5):481-92. PubMed PMID: 7641077.

47: Kongshaug M, Cheng LS, Moan J, Morgan AR. Binding of etiopurpurin and tin-coordinated etiopurpurin to human plasma proteins. Delivery in cremophore EL and dimethyl sulfoxide (paper II). Int J Biochem Cell Biol. 1995 Jan;27(1):71-87. PubMed PMID: 7757884.

48: Selman SH, Keck RW. The effect of transurethral light on the canine prostate after sensitization with the photosensitizer tin (II) etiopurpurin dichloride: a pilot study. J Urol. 1994 Dec;152(6 Pt 1):2129-32. PubMed PMID: 7966701.

49: Sekher P, Garbo GM. Spectroscopic studies of tin ethyl etiopurpurin in homogeneous and heterogeneous systems. J Photochem Photobiol B. 1993 Oct;20(2-3):117-25. PubMed PMID: 8271113.

50: Hampton JA, Skalkos D, Taylor PM, Selman SH. Iminium salt of copper benzochlorin (CDS1), a novel photosensitizer for photodynamic therapy: mechanism of cell killing. Photochem Photobiol. 1993 Jul;58(1):100-5. PubMed PMID: 8378428.

51: Kongshaug M, Moan J, Cheng LS, Garbo GM, Kolboe S, Morgan AR, Rimington C. Binding of drugs to human plasma proteins, exemplified by Sn(IV)-etiopurpurin dichloride delivered in cremophor and DMSO. Int J Biochem. 1993 May;25(5):739-60. PubMed PMID: 8349016.

52: Kessel D, Garbo GM, Hampton J. The role of lipoproteins in the distribution of tin etiopurpurin (SnET2) in the tumor-bearing rat. Photochem Photobiol. 1993 Feb;57(2):298-301. PubMed PMID: 8451293.

53: Ash DV, Brown SB. New drugs and future developments in photodynamic therapy. Eur J Cancer. 1993;29A(12):1781-3. PubMed PMID: 8398311.

54: Mazza P, Orcesi M, Pelizzi C, Pelizzi G, Predieri G, Zani F. Synthesis, structure, antimicrobial, and genotoxic activities of organotin compounds with 2,6-diacetylpyridine nicotinoyl- and isonicotinoylhydrazones. J Inorg Biochem. 1992 Dec;48(4):251-70. PubMed PMID: 1479362.

55: Polo L, Reddi E, Garbo GM, Morgan AR, Jori G. The distribution of the tumour photosensitizers Zn(II)-phthalocyanine and Sn(IV)-etiopurpurin among rabbit plasma proteins. Cancer Lett. 1992 Oct 21;66(3):217-23. PubMed PMID: 1451102.

56: Frazier DL, Barnhill MA, Vodinh T, Legendre AM, Overholt BF. Comparative pharmacokinetics of the photosensitizer tin-etiopurpurin in dogs and rats. J Vet Pharmacol Ther. 1992 Sep;15(3):275-81. PubMed PMID: 1433491.

57: Selman SH, Fitkin DL, Keck RW, Morgan AR, Doiron DR. Treatment of the transplantable FANFT induced bladder tumors with the purpurin SnET2 and red light emitted by a pulsed frequency doubled Nd:YAG laser. J Laser Appl. 1991 Spring;3(2):45-8. PubMed PMID: 10149393.

58: He DP, Hampton JA, Keck R, Selman SH. Photodynamic therapy: effect on the endothelial cell of the rat aorta. Photochem Photobiol. 1991 Nov;54(5):801-4. PubMed PMID: 1798756.

59: Kessel D, Morgan A, Garbo GM. Sites and efficacy of photodamage by tin etiopurpurin in vitro using different delivery systems. Photochem Photobiol. 1991 Aug;54(2):193-6. PubMed PMID: 1780356.

60: Morgan AR, Cheng LS, Skalkos D, Garbo GM. Tin etiopurpurin dichloride-sensitized lipid photooxidation of erythrocyte membranes. Photochem Photobiol. 1990 Nov;52(5):987-91. PubMed PMID: 2287638.

61: Morgan AR, Garbo GM, Keck RW, Eriksen LD, Selman SH. Metallopurpurins and light: effect on transplantable rat bladder tumors and murine skin. Photochem Photobiol. 1990 May;51(5):589-92. PubMed PMID: 2142308.

62: Selman SH, Qin BS, James HR, Keck RW, Garbo GM, Morgan AR. Hemodynamic effect of the metallopurpurin SnET2 and light on transplantable FANFT induced bladder tumor. J Urol. 1990 Mar;143(3):630-3. PubMed PMID: 2304185.

63: Morgan AR, Garbo GM, Keck RW, Selman SH. New photosensitizers for photodynamic therapy: combined effect of metallopurpurin derivatives and light on transplantable bladder tumors. Cancer Res. 1988 Jan 1;48(1):194-8. PubMed PMID: 3334995.